Eye­ing a multi­bil­lion-dol­lar mar­ket, Shire snags pre­clin­i­cal IVIg ri­val from AB Bio­sciences

Shire $SH­PG is get­ting in ear­ly on an in­ves­ti­ga­tion­al prod­uct that might one day re­place IV in­fu­sions of con­cen­trat­ed an­ti­bod­ies giv­en to pa­tients to boost …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA